Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Immunome (IMNM) EBITDA Margin: 2023-2025

Historic EBITDA Margin for Immunome (IMNM) over the last 2 years, with Jun 2025 value amounting to -1,157.61%.

  • Immunome's EBITDA Margin rose 53482.00% to -1,157.61% in Q2 2025 from the same period last year, while for Jun 2025 it was -1,784.14%, marking a year-over-year increase of 73435.00%. This contributed to the annual value of -3,382.37% for FY2024, which is 260102.00% down from last year.
  • According to the latest figures from Q2 2025, Immunome's EBITDA Margin is -1,157.61%, which was up 24.12% from -1,525.50% recorded in Q1 2025.
  • Immunome's 5-year EBITDA Margin high stood at -129.96% for Q3 2023, and its period low was -12,857.05% during Q1 2024.
  • Its 3-year average for EBITDA Margin is -2,492.75%, with a median of -1,608.96% in 2025.
  • As far as peak fluctuations go, Immunome's EBITDA Margin crashed by 1,266,792bps in 2024, and later spiked by 1,133,155bps in 2025.
  • Immunome's EBITDA Margin (Quarterly) stood at -2,473.94% in 2023, then slumped by 55,637bps to -3,030.31% in 2024, then surged by 53,482bps to -1,157.61% in 2025.
  • Its EBITDA Margin was -1,157.61% in Q2 2025, compared to -1,525.50% in Q1 2025 and -3,030.31% in Q4 2024.